Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FFWLJ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,892.90 to DMS Pharmaceutical Group Inc. for NUCALA 100 mg/ml auto-injectors, with a completion deadline of July 22, 2025. This firm fixed-price delivery order was issued without a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge location. The company holds a significant single-award Indefinite Delivery Contract with DLA under the SPE2DB program valued at $499,999,999 through November 2026, which enables the issuance of delivery orders for pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
This delivery order represents a typical transaction under DMS Pharmaceutical Group's master IDC with DLA, supplying specialty pharmaceutical products to military health facilities. NUCALA (mepolizumab) is a monoclonal antibody used for severe eosinophilic asthma and other conditions, reflecting the company's role in distributing both specialty biologics and standard pharmaceuticals to federal healthcare systems. As a established pharmaceutical distributor with continuous federal contracting experience since 2001, DMS Pharmaceutical Group has demonstrated capability in managing complex pharmaceutical supply chains for the Department of Defense.
Quick answers
Who was awarded contract SPE2DB25FFWLJ?
SPE2DB25FFWLJ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 21, 2025.
How much is contract SPE2DB25FFWLJ worth?
The government has obligated $1,893 on SPE2DB25FFWLJ.
Is contract SPE2DB25FFWLJ an order under another contract?
Yes. SPE2DB25FFWLJ is a delivery order under SPE2DB24D9315, an indefinite delivery contract.
Was contract SPE2DB25FFWLJ competed?
The extent of competition for SPE2DB25FFWLJ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award